1 Neurologisk Klinik, Neurocentret, Rigshospitalet, The Capital Region of Denmark2 Klinik for Klinisk Fysiologi, Nuklearmedicin og PET, Diagnostisk Center, Rigshospitalet, The Capital Region of Denmark3 Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany; Leipzig University Medical Center, Integrated Research and Treatment Centre (IFB) Adiposity Diseases, Leipzig, Germany. Electronic address: firstname.lastname@example.org Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.5 Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany.6 Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany; Centre for Clinical Studies, Leipzig, Germany.7 Translational Centre for Regenerative Medicine (TRM) Leipzig, Germany.8 Institute of Nuclear Medicine, University College London Hospital, London, UK.9 Department of Medical Physics and Bioengineering, Southampton University Hospitals NHS Trust, Southampton, UK.10 University of Szeged, Department of Nuclear Medicine and Euromedic Szeged, Szeged, Hungary.11 Department of Nuclear Medicine, Medical University of Vienna, Austria.12 Nuclear Medicine Department, Centre Antoine Lacassagne, University of Nice-Sophia Antipolis, Nice, France.13 Department of Nuclear Medicine, Gazi University, Faculty of Medicine, Ankara, Turkey.14 Clinical Neurophysiology Unit, Department of Neuroscience, Ophthalmology and Genetics, San Martino Hospital, University of Genoa, Genoa, Italy.15 Department of Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden; Institute of Cognitive Sciences and Technologies, CNR, Rome & Padua, Italy.16 Nuclear Medicine Division, Université Catholique de Louvain, Mont-Godinne Medical Center, Louvain-la-Neuve, Belgium.17 Nuclear Medicine, University Hospital, K.U. Leuven, Leuven, Belgium.18 Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden.19 Department of Nuclear Medicine, University of Munich, Munich, Germany; Department of Nuclear Medicine, Municipal Hospital Karlsruhe Inc., Karlsruhe, Germany.20 Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany; Leipzig University Medical Center, Integrated Research and Treatment Centre (IFB) Adiposity Diseases, Leipzig, Germany.21 Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
UNLABELLED: Serotonin-mediated mechanisms, in particular via the serotonin transporter (SERT), are thought to have an effect on food intake and play an important role in the pathophysiology of obesity. However, imaging studies that examined the correlation between body mass index (BMI) and SERT are sparse and provided contradictory results. The aim of this study was to further test the association between SERT and BMI in a large cohort of healthy subjects. METHODS: 127 subjects of the ENC DAT database (58 females, age 52 ± 18 years, range 20-83, BMI 25.2 ± 3.8 kg/m(2), range 18.2-41.1) were analysed using region-of-interest (ROI) and voxel-based approaches to calculate [(123)I]FP-CIT specific-to-nonspecific binding ratios (SBR) in the hypothalamus/thalamus and midbrain/brainstem as SERT-specific target regions. RESULTS: In the voxel-based analysis, SERT availability and BMI were positively associated in the thalamus, but not in the midbrain. In the ROI-analysis, the interaction between gender and BMI showed a trend with higher correlation coefficient for men in the midbrain albeit not significant (0.033SBRm(2)/kg, p=0.1). CONCLUSIONS: The data are in agreement with previous PET findings of an altered central serotonergic tone depending on BMI, as a probable pathophysiologic mechanism in obesity, and should encourage further clinical studies in obesity targeting the serotonergic system.
Journal of European College of Neuropsychopharmacology, 2014, Vol 24, Issue 8, p. 1240-7